Pfizer Inc. (PFE)
After hours:
| Previous Close | 43.97 |
| Open | 43.63 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 4000 |
| Day's Range | 43.50 - 44.46 |
| 52 Week Range | 41.45 - 56.32 |
| Volume | |
| Avg. Volume | 21,887,870 |
| Market Cap | 248.894B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 8.11 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.64 (3.73%) |
| Ex-Dividend Date | Jan 26, 2023 |
| 1y Target Est | N/A |
- Business Wire
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
NEW YORK, January 31, 2023--Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
- Business Wire
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
DAVOS, Switzerland, January 17, 2023--Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.
- Business Wire
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
NEW YORK, January 06, 2023--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of ot
